Contact IR
IR contact
David Miller
Senior Director of Corporate Affairs
investors@angion.com
ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS